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Abstract
Background: The mainstay of treating patients with phenylketonuria (PKU) is based on a Phe-restricted diet,
restrictive in natural protein combined with Phe-free L-amino acid supplements and low protein foods. This PKU
diet seems to reduce atherogenesis and confer protection against cardiovascular diseases but the results from the
few published studies have been inconclusive. The aim of our study was to evaluate the relationship between the
lipid profile and several treatment-related risk factors in patients with hyperphenylalaninaemia (HPA) in order to
optimize their monitoring.
Methods: We conducted a cross-sectional multicentre study. A total of 141 patients with HPA were classified
according to age, phenotype, type of treatment and dietary adherence. Annual median blood phenylalanine (Phe)
levels, Phe tolerance, anthropometric measurements, blood pressure (BP) and biochemical parameters [(triglycerides,
total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C),
apolipoprotein A (ApoA), apolipoprotein B (ApoB), vitamin B12, total homocysteine (tHcy), Methionine (Met), high
sensitivity C-Reactive Protein (hsCRP)] were collected for each patient.
Results: Plasma TC levels were lower in patients with PKU than in the mild-HPA group (150 ± 31 vs. 164 ± 22 mg/
dL), and there was a weak inverse correlation between plasma TC and Phe levels. HDL-C, LDL-C, ApoA and ApoB
levels were lower in the PKU group than in mild-HPA. Patients with PKU had higher systolic BP than the mild-HPA
group and there was found a quadratic correlation between median Phe levels and systolic BP (p = 6.42e-5) and a
linear correlation between median Phe levels and diastolic BP (p = 5.65e-4). In overweight or obese PKU patients (24.
11 %), biochemical parameters such as TC, triglycerides, LDL-C, tHcy, hsCRP and BP were higher. By contrast, HDL-C
was lower in these patients.
Conclusion: Our data show a direct correlation between lipid profile parameters and good adherence to the diet
in PKU patients. However, lipid profile in overweight or obese patients displayed an atherogenic profile, in addition
to higher hsCRP concentrations and BP. Our study contributes to a better understanding of the relationship
between phenotype and treatment in patients with HPA, which could be useful in improving follow-up strategies
and clinical outcome.
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Background
Phenylketonuria (PKU; MIM 261600), an autosomal
recessive disorder of Phenylalanine (Phe) metabolism, is
mainly caused (98 % of cases) by deficient activity of the
hepatic enzyme L-phenylalanine-4-hydroxylase (PAH;
EC 1.14.16.1), due to mutations in the PAH gene (NM
000277.1). Loss of PAH activity results in increased
blood Phe concentrations which leads to irreversible
neurological damage if it is untreated. Average incidence
in Caucasians is of 1 in 10,000 individuals [1]. Hyperphe-
nylalaninaemia (HPA) is usually diagnosed by Newborn
Screening Programme, routinely performed in Spain since
1980 [2], which enable early diagnosis and treatment. Pre-
established thresholds for plasma Phe concentrations
according to age are not yet standardized and vary among
countries [3, 4].
Despite the appearance of novel approved treatment
approaches (for example, large neutral amino acids,
(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (6R-BH4) and
glycomacropeptide), dietary intervention remains the
mainstay of treating patients with PKU [5]. Patients are
typically recommended to follow a PKU diet based on
low Phe intake. This diet consists of a marked reduction
in natural protein, with supplementation with Phe-free
amino acid mixture.
There is a general agreement that patients with PKU
require long-term dietary counselling as well as daily
nutritional supplementation [5]. This diet has some
drawbacks, such as the poor organoleptic properties
(taste, scent) of the Phe-free protein substitutes and
special-manufactured low-protein foods which are likely
to have a negative effect on compliance with the diet.
Furthermore, long-term safety of this dietary treatment
as well as its potential association with risk of non-
communicable diseases in later stages should be further
investigated [6]. In this regard, there are several recently
published reports about the contribution of mineral and
vitamin status [7–11]. However, very few studies have
explored the blood lipid profile in PKU [12, 13]. In
particular, it has been observed that PKU children
who had good adherence to diet, consumed saturated
(below 7 %) and polyunsaturated (above 5 %) fats
from total daily energy with amounts below 50 mg of
cholesterol per day [14].
The aim of our study was to determine the blood lipid
profile status and several cardiovascular-related risk
factors, such as overweight/obesity, plasma total homo-
cysteine (tHcy) levels, high-sensitivity C-reactive protein
(hsCRP), micronutrients (zinc (Zn) and cupper (Cu))
and blood pressure (BP) in patients with PKU, who were
classified into groups according to Phe tolerance, 6R-BH4
supplementation and adherence to diet. Moreover, we




A total of 141 patients were enrolled in this cross-
sectional multicentre study between February 2015 and
February 2016 from three Metabolic Diseases Unit at
three Spanish Hospitals: Hospital Universitario La Fe
(Valencia) (n = 62), Hospital Universitario Cruces (Basque
Country) (n = 23) and Hospital Clínico Universitario de
Santiago (Galicia) (n = 56). The study protocol was ap-
proved by the Research Ethics Committee of Santiago-
Lugo (2015/393). Written informed consent was obtained
from parents or legal guardians of children (below
16 years of age) and patients included. Patients were
followed in their respective Centre from the date of
diagnosis up to current date. The study included both
patients who were diagnosed through Newborn Screen-
ing Programmes as well as patients who were later
diagnosed due to the appearance of clinical symptoms.
Exclusion criteria were: (1) poor medical monitoring,
changes in amino acid mixture during the month prior
to enrolment and (3) pregnancy.
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Data collected for each patient were: age, gender,
phenotype [patients were classified into phenotypic
categories according to blood Phe levels, which were
measured at diagnosis, based on US Guidelines [15]:
mild-hyperphenylalaninaemia (MHPA), (120–360 μmol/
L); mild-moderate PKU (MPKU), (360–1200 μmol/L)
and classic PKU (CPKU), (>1200 μmol/L)], diagnosis
time (early versus late diagnosis), annual median blood
Phe levels (pre-established “safe” thresholds: <360 μmol/
L for children below 6 years of age; <480 μmol/L for
those from 6 to ≤10 years of age and ≤600 μmol/L for
those >10 years of age) [2], anthropometric characteristics
[weight, height, body mass index (BMI), waist circumfer-
ence (WC) and mid-upper arm circumference (AC)], Phe
tolerance (low <500 mg/day, high >500 mg/day), 6R-BH4
therapy (treated vs. non-treated), systolic and diastolic
blood pressure (SBP and DBP), and blood biochemical
measurements such as: triglycerides (TGC), total choles-
terol (TC), high-density lipoprotein cholesterol (HDL-C),
low density lipoprotein-cholesterol (LDL-C), apolipoprotein
A (ApoA), apolipoprotein B (ApoB), Zn, Cu, vitamin B12
(B12), total homocysteine (tHcy), Methionine (Met). LDL
cholesterol/ApoB and Zn/Cu ratios were calculated. High-
sensitivity C-Reactive Protein (hsCRP) was measured in 55
patients. Blood samples for the measurements were ob-
tained after overnight fasting at the same time (8:00 h in
the morning) from patients without acute infection or
medication (except from patients on 6R-BH4 therapy). Ref-
erence range values (valid for all ages) for micronutrients
were: vitamin B12 (180-1900 pg/mL); Zn (65- 140 μg/dL);
Cu (65-140 μg/dL); tHcy (5-15 μmol/L); hsCRP (0-1.1 mg/
dL) and Met (10-60 μmol/L for patients < 18 years of age;
20-37 μmol/L for patients > 18 years of age). With regard to
cardiovascular parameters the upper thresholds were:
TC > 200 mg/dL, LDL-C > 130 mg/dL; ApoB ≥ 110 mg/dL
and TGC > 100 mg/dL for patients from 0 to 9 years of
age and >130 mg/dL for patients >10 years of age. Lower
thresholds were: TGC < 30 mg/dL; HDL-C < 40 mg/dL
and ApoA < 115 mg/dL. Adherence to treatment in pa-
tients with PKU was established according to their meta-
bolic control by annual median blood Phe levels and the
pre-established “safe” thresholds for each age (as above
mentioned) [2]. Definition and staging of high blood pres-
sure (BP) in children and adolescents were based on BP at
presentation according to US National High Blood Pres-
sure Education Program [16]. High blood pressure was
defined as systolic BP (SBP) and/or diastolic BP (DBP)
above the 95th percentile according to gender, age, and
height; while prehypertension was defined as SBP and/or
DBP from the 90th to 95th percentile on repeated mea-
surements. Diagnosis of essential hypertension in adults
was established according to definitions provided by the
European Society of Hypertension and the European Soci-
ety of Cardiology guidelines [17].
Methods
The three Centres followed the same protocol. Dietary
treatment was based on recommendations in the Spanish
Guidelines for treating and monitoring patients with PKU
[2]. That is, patients are typically recommended to follow
a PKU diet, which consists of a marked reduction in nat-
ural protein diet, and supplementation with Phe-free
amino acids mixture. Average protein intake was 1.3-1.5
times above Recommended Dietary Allowances (RDA)
[18]. Nutritional diet was weekly assessed by 3-day food
surveys completed using software www.odimet.es. The
group of MHPA patients, who had Phe levels at diagnosis
of 120-360 μM/L, did not require treatment and therefore
they followed a normal diet.
Recumbent length was measured with a measuring
board and weight with a manual baby scale until the age
of 24 months. Thereafter, standing height was measured
with a wall-mounted stadiometer and body weight, with
digital scales. Patients were weighed barefoot and after
overnight fasting. The nutritional status was assessed by
calculating the body mass index (BMI) using the formula
BMI = weight (kg) /height2 (m2). Patients above 18 years
of age were classified based on World Health Organization
(WHO) criteria as: underweight (BMI < 18.5), normal
weight (BMI 18.5-24.99), overweight (BMI 25-29.99), and
obese (BMI ≥ 30). Patients below 18 years of age were
classified according to BMI using the WHO Child Growth
Standards (Underweight: BMI below the 15th percentile;
Normal: BMI from the 15th to 85th percentiles, Over-
weight: BMI from the 85th to 95th percentiles, Obese: BMI
above the 95th percentile) [19, 20].
Waist circumference (WC) was measured at a level
midway between the lower rib margin and the iliac crest
and mid-upper arm circumference (AC) was measured
at a point half-way between the elbow and the shoulder.
These measurements (expressed in cm) were stratified
according to gender and age based on the previously
published study in children named Estudio Galinut [21].
In adult patients, specific values for WC and AC were
used from the International Diabetes Federation (IDF)
[22] and Frisancho’s study [23], respectively.
Phe levels from dried blood spots and plasma samples
were measured using Tandem mass-spectrometry. TC,
HDL-C and TGC concentrations were determined by
standard procedures using an Advia 2400 Analyzer
(Siemens Diagnostic Systems, Germany). When TGC
levels were < 350 mg/dL, LDL-C was estimated using
the Friedewald formula LDL = TC - HDL-C - TG/5.0
(mg/dL). When TGC levels were >350 mg/dL, LDL-C
was estimated by a direct method which was based on
cholesterol oxidase, esterase and peroxidase, once lipo-
protein cholesterol (other than LDL) were removed
using an Advia 2400 Analyzer (Siemens Diagnostic
Systems, Germany). Vitamin B12 was determined using
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an Advia Centaur XP Analyzer (Siemens Healthcare Diag-
nostics, Erlangen, Germany), Zn and Cu using a 7700 ICP-
Mass Spectrometry System (Agilent, CA, USA). Plasma
ApoA and ApoB levels were measured by immunonephe-
lometry assay using a Dimension Vista™ 1500 Analyzer
(Siemens Healthcare Diagnostics) and tHcy concentrations
were determined in EDTA-plasma samples by a competi-
tive immunoassay using an IMMULITE® 2000 Analyzer
(Siemens Healthcare Diagnostics). hsCRP levels were deter-
mined by spectrophotometry.
BP was measured using an oscillometric device (Omron
IT-750; Omron Healthcare, Tokyo, Japan) and an appro-
priate cuff was applied in the supine position after a rest-
ing period of 5min. Patients were asked not to practice
any physical activity and to avoid caffeinated beverages
prior to medical appointments. Simultaneous supine mea-
surements at both arms were recorded, and shortly after-
ward three additional supine measurements were taken at
the arm with displayed the higher BP. Average of the last
two measurements was used for data analysis.
Statistical test
In order to determine significant associations and/or
differences between the different variables measured,
the following methods were applied: first of all, we used
the Kolmogorov–Smirnov and the Shapiro–Wilk tests
to determine if the groups follow a normal distribution.
Later, if one of the variables was quantitative and the
other qualitative, we applied the Student t-test or the
ANOVA if the quantitative variable was normal, and
the Wilcoxon signed-rank or the Kruskal–Wallis test
otherwise. If both variables were quantitative, under
normality assumptions we fitted a linear regression
model, and the p-value is the significance level of the
adjustment; if the data wasn’t normal, we used the
Kruskal–Wallis test. In the case that both variables
were qualitative we used Fisher’s exact test. Finally, we
adjusted the obtained p-values using the Benjamini-
Hochberg correction. Only adjusted p-values lower
than 0.05 were considered significant. Statistical ana-
lysis was performed using R Core Team [24], version
3.2.3.
Results
Our study included 141 patients with HPA [67 (47.5 %)
males; range age: 6 months-50 years; mean age: 15 years
6 months]. There were 100 patients (71 % of our popula-
tion) who were diagnosed with PKU and 41 (29 %) with
MHPA. In the group of patients with PKU, 66 (66 %)
were classified as CPKU and 34 (34 %) as MPKU. A total
of 16 (11.3 %) of our patients were diagnosed at a later
stage by the appearance of clinical symptoms, due to the
fact that in Spain the Newborn Screening Program for
PKU started in the 70-80’s. With regard to 6R-BH4
therapy, 17 (17 %) of the patients with PKU were treated,
out of them 14 (82.3 %) were classified as MPKU.
Over the observation period, adequate dietary adher-
ence was observed in 120 patients (85.1 % of our popu-
lation); in the group of patients below 10 years of age
(63), 56 (88.9 %) had adequate dietary adherence;
whereas in the group of patients above 10 years of age
(78), 14 (18 %) had low dietary adherence,13 (92.8 %) of
these patients were above 18 years of age [5 (62.5 %) of
them where diagnosed at a later stage]. Only 1 (5.9 %)
out of the 17 patients who were on 6R-BH4 treatment
displayed Phe levels slightly above the pre-established
“safe” threshold for their age ((P.23) Table 1 and
Additional file 1).
With regard to blood lipid profile, TGC deficiency was
observed in only 2 patients (1.4 %), but it was at the
upper threshold in 26 patients (18.4 %), none of them
was on 6R-BH4 treatment. Nevertheless, TC was de-
creased in 19 patients (13.5 %) (100 % of them were
patients with PKU), out of them 14 (73.7 %) were below
18 years of age and 16 (84.2 %) of them had an adequate
adherence to treatment. Similarly, HDL-C, LDL-C,
ApoA and ApoB concentrations were below the low
threshold in the PKU group compared with the MHPA
group (Table 2, Fig. 1). However, in the group of PKU
patients, those who had a good metabolic control
displayed higher HDL-C concentrations and LDL/ApoB
ratio than those with poor metabolic control (50.4 ± 12.02
vs. 47.4 ± 11.26 mg/dL and 1.22 ± 0.19 vs. 1.20 ± 0.23,
respectively); although these differences did not reach
statistical significance.
B12 levels were in the normal range or even slightly
elevated in all patients; Cu and Zn levels were decreased
in 31 (22 %) and 28 (19.9 %) patients, respectively. In
the group of patients with low Cu levels, 18 (58.1 %)
were CPKU and in the group with low Zn levels, 13
(46.4 %) were CPKU; all of them received Phe free
formula. Plasma tHcy levels were elevated only in two
PKU patients, both of them displayed B12 levels in the
normal range (362 pg/mL and 237 pg/mL, respectively),
whereas its levels were decreased in 58 patients (41.1 %),
mainly in patients with an adequate adherence to treat-
ment (50 patients, 86.2 %) and with lower Phe tolerance
(44 patients, 75.9 %). hsCRP was elevated in 4 patients
(2.84 %), all of them were PKU patients who were on
dietary treatment, above 18 years of age and with over-
weight/obesity. Met levels were in the normal range for
all the patients (26.96 ± 4.2 μmol/L).
Children and adults patients with PKU had higher sys-
tolic blood pressure (114.9 ± 14.4 vs. 105.5 ± 12.03 mmHg;
p = 0.0438) than patients with MHPA. Although diastolic
blood pressure was also higher in the PKU group
compared with the MHPA group (69.3 ± 13.65 vs. 65.7 ±
10.49 mmHg), this difference did not reach statistical
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significance. It is worth mentioning that a statistically
significant quadratic correlation was observed between
median Phe and systolic BP (p = 6.42e-5), and a lin-
ear correlation between median Phe and diastolic
BP (p = 5.65e-4), both in patients below and above
18 years of age (Fig. 2).
With regard to body mass index (BMI), 47 patients
(33.33 %) did not have an adequate BMI Z-score, which
had a value below the lower threshold in 10 patients
(7.1 %) and above the upper threshold in 37 patients
(26.24 %) [25 (67.6 %) were overweight and 12 (32.4 %)
were obese]. Waist circumference (WC) was above the
recommended threshold in 52 (36.9 %) patients [27
(51.9 %) of them above the 95th percentile). Arm cir-
cumference (AC) was elevated in 26 (18.4 %) patients
[11 (42.3 %) of them above the 95th percentile). The per-
centage of patients with elevated BMI Z-score and WC
was significantly higher in the group of PKU patients
compared with the MHPA group [34 (91.9 %) vs. 3
(8.1 %), p = 0.005 for BMI Z-score; and 45 (86.5 %) vs. 7
(13.5 %), p = 0.007 for WC]. When age of patients was
considered, we observed that patients who had an ele-
vated BMI Z-score were all above 18 years of age [37
(100 %) vs. 0 (0 %), p = 4.57e-23), and that a higher per-
centage of patients above 18 years of age had WC above
the recommended thresholds [34 (65.4 %) vs. 18
(34.6 %), p = 5.63e-7], with only 2 (6.25 %) patients di-
agnosed with PKU. Furthermore, BMI Z-score, AC
and WC were also statistically significantly higher in
patients with good metabolic control compared to pa-
tients with poor metabolic control: 26 (70.3 %) vs. 11
(29.7 %) (p = 0.011) for BMI Z-score; 39 (76.9 %) vs.
13 (23.1 %) (p = 0.048) for AC; and 19 (75 %) vs. 4
(25 %) (p = 0.035) for WC (Fig. 3).
Biochemical parameters such as TC, TGC, LDL-C,
tHcy and BP were higher in overweight or obese patients
with PKU. By contrast, HDL-C was lower in these
patients (Fig. 4). Levels of hsCRP were elevated in 4 out
of the 55 analysed patients (7.27 %), all of them with
overweight/obesity. No statistically significant differences
between the underweight and the normal nutritional
status groups were found, except from WC, which was
lower in the group of patients with underweight and
below 18 years of age (p = 0.007). With regard to 6R-
BH4 treatment, statistically significant differences in
HDL-C levels were observed between the 6R-BH4-
treated and the non-treated group (mean: 60.65 ± 14.04
vs. 50.28 ± 11.61 mg/dL, p = 0.0367).
Discussion
Reduction of animal origin lipids and cholesterol intake,
which is one of the main characteristics of the PKU
diet, could be considered to be the definition of non-
atherogenic diet [12]. To support this hypothesis, pre-
viously published studies have suggested a similar or
even improved lipid profile in PKU children com-
pared to healthy controls [25]. Only few studies have
explored lipid profile or other coronary heart disease-
related parameters in PKU patients. Taking into ac-
count that PKU patients require a lifelong treatment,
we consider that special attention and further investi-
gations are required.
Our findings did not show significant differences in
TGC levels between the PKU and MHPA groups of
Table 1 Clinical and biochemical parameters for patients with
MHPA and PKU; BMI body mass index, WC waist circumference,
AC arm circumference, BP blood pressure
MHPA PKU
Number patients 41 100
Gender – Male 20 47
Gender – Female 21 53
Average Age 9y 7 m 17y 10 m
Under 18 years 35 57
zBMI – obese + overweight 3 34
zBMI – normal 33 61
zBMI – underweight 5 5
WC - obese + overweight 7 45
WC - normal 30 50
WC - underweight 4 5
AC - obese + overweight 5 21
AC - normal 21 27
AC - underweight 4 15
Early Diagnostic 40 85
BH4 treatment 0 17
Adequated Diet adherence 40 80
Phe Tol (mg/day) 1889.6 ± 831.9 481.1 ± 376.3
Phe median (μmol/L) 238.6 ± 93.2 397.3 ± 281.9
Total Cholesterol (mg/dL) 164.2 ± 21.9 149.9 ± 31.5
HDL (mg/dL) 55.8 ± 12.6 49.8 ± 11.9
LDL (mg/dL) 92.1 ± 17.2 82.1 ± 24.7
ApoA (mg/dL) 160.7 ± 26.4 144.1 ± 25.9
ApoB (mg/dL) 75.5 ± 17.6 65.9 ± 19.1
LDL/ApoB 1.26 ± 0.16 1.22 ± 0.19
Triglycerids (mg/dL) 79.2 ± 36.2 91.7 ± 45.7
Homocystein (μmol/L) 5.9 ± 2.4 5.9 ± 3.3
Systolic BP (mmHg) 105.5 ± 12 114.9 ± 14.4
Diastolic BP (mmHg) 65.7 ± 10.5 69.3 ± 13.7
B12 (pg/mL) 584.9 ± 205.6 664.5 ± 333.6
Zinc (μg/dL) 82.4 ± 33.1 81.2 ± 21.5
Copper (μg/dL) 86 ± 22.5 78.4 ± 21.3
Zinc/Copper 1.01 ± 0.46 1.11 ± 0.45
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lipoprotein cholesterol, LDL-C low- density lipoprotein cholesterol, ApoA apolipoprotein A, ApoB apolipoprotein B, tHcys total homocysteine, Zn Zinc, Cu Cupper, B12 vitamin B12, hsCRP high sensitivity C-Reactive Protein,















patients. Levels of total cholesterol (TC) in PKU children
with good metabolic control have been assessed in few
studies and their results have been inconclusive.
Whereas in some of these studies have reported that
PKU children on diet displayed lower TC levels com-
pared with healthy controls [12, 26]; in one particular
study there was no difference in TC levels between PKU
and healthy children [13] and in another study TC levels
were higher in patients with PKU [27]. In this present
study, we showed that plasma TC levels were lower in
the group of PKU patients than in the MHPA group. It
should be pointed out that serum and tissue cholesterol
concentrations depend on both a vegetarian diet, whose
main sources of lipid are olive oil and cream cheese, and
on cholesterogenesis [26, 28]. Furthermore, there are
several regulatory mechanisms which contribute to chol-
esterol homeostasis. Although in this study we have only
analyzed the blood lipid profile of patients with PKU, it
is worth mentioning that an in vivo study, in which
experimental hyperphenylalaninemia was induced in an
animal model, demonstrated that there was an inhibition
of two of the main regulatory enzymes of brain and liver
cholesterogenesis: 3-hydroxy-3-methylglutaryl-CoA re-
ductase and mevalonate-5-pyrophosphate decarboxylase
[29]; and therefore a reduced cholesterol synthesis in the
brain may indicate an association between impaired
myelination and mental retardation in patients with PKU.
In contrast with other studies, which did not observe
differences in plasma HDL levels in PKU children com-
pared to controls [30–32], we found that HDL-C and
ApoA levels were statistically significantly lower in PKU
patients. However, LDL-C and ApoB levels were sta-
tistically significantly lower in the group of PKU pa-
tients, which is an indicator of low atherogenic risk. In
addition, LDL-C/ApoB ratio was higher in PKU patients
who had good dietary compliance. In this regard, it is
worth mentioning that Campos et al.’s study [33] sug-
gested that a high LDL-C/ApoB ratio usually correlates
with the presence of larger and less atherogenic LDL
particles, which are less susceptible to oxidative damage
than small LDL particles. No clinical data of ischemic
disease or other cardiovascular findings were observed
in our patients, although it should be pointed out that
only nine of them were between 40 and 50 years of age.
It has been previously reported that high serum Cu
and low serum Zn concentrations were significantly
associated with an increased mortality rate from all
cardiovascular diseases and from coronary heart disease
Fig. 1 Lipid profile in patients with phenylketonuria vs. patients with mild hyperphenylalaninaemia. Box-plot diagrams showing the levels measured at
diagnosis: a) Total Cholesterol (mg/dL), b) high-density lipoprotein (HDL)-Cholesterol (mg/dL), c) low density lipoprotein (LDL)-Cholesterol (mg/dL),
d) Apolipoprotein-A (mg/dL) and e) Apolipoprotein-B (mg/dL). Box-plots show median values (solid horizontal line); 25th and 75th percentiles (box);
minimum and maximum values (bars); outliers (open circles). The * indicates the statistical significant differences: * p < 0.05, using the statistical tests
described in the Methods Section. PKU: phenylketonuria; MHPA: mild hyperphenylalaninaemia
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in particular [34]. In our study, we observed that only
three patients had high Cu levels and 28 (19.9 %) of our
patients had low serum Zn levels. Furthermore, a study
in a rat animal model showed that low Cu levels were
associated with the presence of larger LDLs and high
serum CT, since this metal modulates the enzymatic
activity of 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase, which is involved in cholesterol biosynthesis
control [35].
Consistent with a previously published study [6], our
data confirmed decreased plasma tHcy levels in PKU
patients who have a good dietary compliance; and this
was observed with methionine levels in the normal
range for all the ages, including adult patients. In con-
trast, Schulpis et al.’ study observed that PKU patients
on strict diet had moderate hyperhomocysteinaemia,
which was probably due to the fact that these patients
displayed low levels of vitamin B12 and folate, both
essentials in Hcy metabolism [36].
Since it has been suggested that CRP levels could
be considered to be an early endothelial dysfunction
biomarker [37], we measured hsCRP, an inflammatory
biomarker. We found elevated levels of hsCRP in 4
PKU adult patients with overweight/obesity.
Based on the fact that high blood pressure in adoles-
cence or young adulthood is strongly related to later risk
of stroke or coronary heart disease, independently of
blood pressure in mid-life [30], in our present study, all
patients displayed a statistically significant quadratic cor-
relation between median Phe and systolic blood pressure
Fig. 2 Correlations between systolic and diastolic blood pressures and mean phenylalanine levels in patients with phenylketonuria and mild
hyperphenylalaninaemia. a Quadratic correlation between systolic blood pressure and median Phe levels. Statistical significance was observed
(p < 0.001). b Linear correlation between diastolic blood pressure and median Phe levels. Statistical significance was observed (p < 0.001). Phe:
phenylalanine (μmol/L); BP: blood pressure (mmHg)
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and a statistically significant linear correlation be-
tween median Phe and diastolic blood pressure. It
should be pointed out that only few studies have
shown low diastolic blood pressure in patients with
PKU on dietary treatment [14, 30]. This may be due
to the fact that the evolution period was short and
that studies on blood pressure in adults PKU are
very scarce.
As far as overweight and obesity is concerned, there
are several reports which suggested a clear tendency
towards overweight and obesity in patients with PKU
[32, 38–40], according to their BMI values. In this re-
gard, we observed in our cohort that BMI Z-score
and WC were higher in the group of PKU patients
compared to the MHPA group. In fact, the AC, which
is a strong indicator of caloric and protein sources
because it reflects fat content and muscle, was ele-
vated in 16.31 % of our PKU patients. Although a
control group was not included in our study, when
our results were compared to the nutritional status in
the Spanish general population [41], we observed that
the BMI Z-score is higher in our patients. Indeed,
37 % of our patients above 18 years of age had an
elevated BMI Z-score, whereas in Spain it is a 26.7 %
of the general population. In this line of research,
Mazola et al. [42] showed similar BMI in patients
with PKU compared with controls, but only 48 % of
the patients in that study had good metabolic control.
In our study, although a control group without PKU
or MHPA was not included, we found that the BMI
Z-score was statistically significantly higher in patients
with good metabolic control compared to patients
with poor metabolic control. This fact may be associ-
ated with protein substitutes intake and commercial
low-Phe products, which most of them have a high
caloric content.
Moreover, BMI Z-score significantly correlated with
several cardiovascular risk factors such as elevated levels
of TGC, tHcy and high BP. On the other hand, it was
observed that patients under 6R-BH4 treatment, and
therefore on a less restricted diet, had a clear tendency
towards normal values of these parameters.
Fig. 3 Body mass index, waist and arm circumference at diagnosis and in relation with median Phe levels in mild hyperphenylalaninaemia and
phenylketonuria. The X-axis indicates the comparison between normal and overweight-obese groups in our population. The Y-axis indicates the
number of patients. a Body mass index Z-score, b) Waist circumference and c) Arm circumference were measured at diagnosis in patients with
mild hyperphenylalaninaemia ( ) and phenylketonuria ( ). d Body mass index Z-score, e) Waist circumference and f) Arm circumference in
relation with median Phe levels (μmol/L) in patients with poor ( ) and good ( ) metabolic control. Statistical significance was observed: * p < 0.05
and ** p < 0.01, using the Fisher’s exact test and the Benjamini-Hochberg correction. PKU: phenylketonuria; MHPA: mild hyperphenylalaninaemia; BMI:
body max index; Phe: phenylalanine
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Conclusions
Our findings demonstrated that PKU patients, who had
good adherence to their diet, are not at risk of develop-
ing atherosclerosis because the levels of their lipids,
lipoproteins and apoliproteins indicated a less athero-
genic profile. Nevertheless, a high percentage of patients
with low Phe tolerance and good dietary compliance
were overweight or obese and showed elevated levels of
atherogenic biochemical markers in addition to high
tHcy levels and BP. These findings highlight the import-
ance that in PKU patients it is safe to avoid overweight
and obesity and advisable to monitor blood pressure,
homocysteine and inflammatory biomarkers levels as well
as others potential cardiovascular risk factors.
Additional file
Additional file 1: Characteristics of Hyperphenylalaninaemia patients
with altered values of the biochemical parameters studied. (DOCX 85 kb)
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